ORUKA THERAPEUTICS INC (ORKA) Stock News
NASDAQ:ORKA - Nasdaq - US6876041087 - Common Stock - Currency: USD
ORKA Latest News, Press Relases and Analysis
Fertility financing 101: How to afford IVF
Financing fertility treatments like IVF can get pricey. Here’s how to afford your family planning.
H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT
On May 27, Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on MoonLake Immunotherapeutics (NASDAQ:MLTX) while keeping the price target unchanged at $100. The reiteration is based on the company’s Sonelokimab candidate, which is currently in Phase 3 with topline data release anticipated soon. Selvaraju highlighted the upcoming release of top-line data from […]
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial
On May 27, analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) while keeping the price target at $45. The reiterated bullish sentiment comes after the company initiated the dosing of its OKRA-002 trial ahead of the schedule. Kapoor noted the early start of dosing for OKRA-002 to be […]
Airwallex Raises $300M As It Expands In U.S. And Latin America, Now Valued At $6.2B With Clients Like Shein And Xero
Payments startup Airwallex announced Wednesday that it secured a new $300 million funding round, pushing its valuation to $6.2 billion. Founded in 2015, Airwallex has grown into a global player by helping businesses send, receive, and manage international payments at scale, Reuters reports. With a network spanning more than 150 countries, the company now reports over $1.2 billion in total funding, with investors of the latest round including major names like DST Global, Square Peg, Lone Pine Cap
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing...
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical...
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data...
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to...
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025,...
Oruka Therapeutics to Present at Multiple March Investor Conferences
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company...
Oruka Therapeutics to Present at Multiple March Investor Conferences
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis...
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel...
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
Mentions: NBI
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001...
Oruka Therapeutics to Present at Multiple November Investor Conferences
MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel...
Oruka Therapeutics to Present at Multiple November Investor Conferences
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent...
Oruka Therapeutics Announces $200 Million Private Placement
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company...